Marcin Miszczyk

PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review

Take Home Message PSMA PET-derived volumetric data hold the potential to personalize treatment strategies depending on treatment response. Comprehensive data on PSMA expression dynamics, however, are still needed before this approach can be implemented in routine clinical practice.

Prognostic Stratification in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line Androgen Receptor Pathway Inhibitor–Based Combination Therapy

We aimed to stratify clinical risk among patients with high‐volume metastatic hormone‐sensitive prostate cancer (mHSPC) treated with first‐line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).

PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer.

BACKGROUND AND OBJECTIVE Prostate-specific membrane-antigen positron emission tomography (PSMA-PET) detects distant metastases in more than half of patients with increasing prostate-specific antigen despite castrate levels of testosterone and high-risk nonmetastatic disease on conventional imaging. Here, we aim to eval...

Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease.

Impact of Gleason Grade at the Positive Surgical Margin on Biochemical Recurrence After Radical Prostatectomy in pT2N0 Prostate Cancer.

GG at the PSM independently predicts BCR, with the strongest effect in lower-grade tumors (ISUP 1-2; HR 7.08 for GG4), attenuated in high-grade disease (HR 2.98).

Diet and risk of bladder cancer: a systematic review of epidemiological evidence.

Available evidence does not support a strong or consistent association between dietary factors and bladder cancer (BC) risk, and patients should be informed that dietary modifications alone are unlikely to meaningfully alter their BC risk.

Predictive biomarkers for immunotherapy response in renal cell carcinoma: why have they failed?

Current limitations in the development of consistent predictive biomarkers are outlined and future progress will require biomarker-stratified prospective trial designs with prespecified endpoints and rigorous external validation to establish clinically meaningful biomarkers.